Related by context. All words. (Click for frequent words.) 70 pharmacodynamic endpoints 69 Primary endpoints 69 secondary efficacy endpoints 69 pharmacodynamic parameters 69 Meta analyzes 69 metabolic parameters 68 Secondary efficacy endpoints 67 Secondary endpoints 67 meta regression 66 symptomatic VTE 66 STRIDE PD 66 Tumor Response 66 prognostic variables 66 lipid parameters 65 trials RCTs 65 MoxDuo TM IR 65 prespecified secondary 65 Candesartan 65 antioxidant supplementation 65 somatic symptoms 65 Efficacy endpoints 65 Echocardiographic 64 CIMZIA ™ 64 Brief Psychiatric 64 haematologic 64 convergent validity 64 hematologic parameters 64 Hematologic 64 PROactive study 64 Scale PANSS 64 BEXXAR Therapeutic Regimen 64 lipid lowering agents 64 riociguat 64 inflammatory biomarkers 64 HRQL 64 β blockers 64 secondary efficacy endpoint 64 hemorrhagic complications 64 HAMD 64 Cardiotoxicity 64 AST ALT 64 Montgomery Asberg Depression 64 hyperoxaluria 64 pharmacokinetic parameters 63 QTc prolongation 63 nonpharmacologic 63 randomized controlled trials RCTs 63 postoperative AF 63 pyridostigmine 63 metabolite concentrations 63 prospectively defined 63 fosbretabulin 63 ATACAND 63 electrophysiologic 63 BCR ABL mutations 63 dyslipidaemia 63 colorectal adenoma 63 neurocognitive function 63 plasma pharmacokinetics 63 intravascular hemolysis 63 clevidipine 63 Negative Syndrome 63 genotypic resistance 63 prospective observational studies 63 Pharmacodynamic 63 F FDG PET 63 myopathy rhabdomyolysis 63 coronary stenosis 62 glycosylated hemoglobin HbA1c 62 postoperative morbidity 62 MYCAMINE 62 posttest 62 Index CDAI 62 dose atorvastatin 62 Fracture Risk 62 psychopathological symptoms 62 desvenlafaxine succinate 62 hematological parameters 62 VADT 62 CPAP adherence 62 serum phosphorous 62 tissue oxygenation 62 PASI scores 62 prospective multicenter study 62 Fibromyalgia Impact Questionnaire 62 hepatic function 62 Depressive Symptoms 62 oral FTY# 62 glucose insulin 62 Events MACE 62 YMRS 62 covariate 62 HRQOL 62 perioperative complications 62 teriflunomide 62 tumor necrosis 62 multivariate logistic regression 62 serum triglycerides 62 Valsartan 62 serum leptin 62 hepatic cirrhosis 62 eculizumab therapy 62 depressive symptom 62 demonstrated clinically meaningful 62 liver histology 62 antihypertensive therapy 62 perfusion abnormalities 62 ADAS Cog 62 hemodynamic measurements 62 specified secondary endpoints 62 FOLPI 62 tolerability profiles 62 HAM D# 61 COPD exacerbations 61 Myocardial Perfusion Imaging 61 venous thromboembolic disease 61 oncologic outcomes 61 pharmacokinetic PK 61 myocardial perfusion 61 Catheter Associated 61 relapsed MM 61 virologic responses 61 paricalcitol 61 myocardial viability 61 UPDRS motor 61 erythropoietic 61 selenium supplementation 61 prospective multicentre 61 postintervention 61 antiepileptics 61 secondary endpoints 61 progressive MS SPMS 61 clinically meaningful reductions 61 multivariate analyzes 61 Functional Outcomes 61 coadministration 61 hepatic enzymes 61 Subgroup analysis 61 vasomotor symptoms 61 multicenter trials 61 neurodevelopmental outcome 61 psychosocial functioning 61 virological response 61 Cardiopulmonary bypass 61 Zevalin consolidation 61 echocardiographic parameters 61 Crohn Disease Activity 61 multiple logistic regression 61 direct thrombin inhibitors 61 bone marrow fibrosis 61 cognitive domains 61 myocardial ischemia 61 Alzheimer Disease Assessment 61 STEP BD 61 methodologic 61 angiographic outcomes 61 probiotic supplementation 61 Cystatin C 61 Subgroup analyzes 61 triiodothyronine 61 atherogenic dyslipidemia 61 APTIVUS r 61 BENICAR HCT 61 Sociodemographic 61 Multivariate logistic regression 61 Nesiritide 61 pulmonary capillary wedge 61 placebo controlled studies 61 Histologic 61 postoperative chemotherapy 61 Septic Shock 61 subscores 61 Pharmacokinetic parameters 61 serum cortisol 61 antiplatelet therapies 61 AGILECT R 61 Lp PLA 2 61 diabetic polyneuropathy 61 metaanalysis 61 Clinical Outcome 61 Renal Function 61 guanfacine extended release 61 inotropic 61 subgroup analyzes 61 macrovascular events 61 comorbid depression 61 enzyme immunoassay EIA 61 Ranolazine 61 intact parathyroid hormone 61 corticosteroid therapy 61 venlafaxine Effexor 61 cardiac autonomic 61 pharmacodynamic PD 61 hypercholesterolaemia 61 MERLIN TIMI 61 pharmacokinetic PK profile 60 antiepileptic drugs AEDs 60 autonomic dysfunction 60 NWEA MAP 60 Secondary endpoints include 60 LDL Cholesterol 60 C Reactive Protein 60 SGRQ 60 cerebral perfusion 60 Pharmacokinetic PK 60 Angiographic 60 Hypercholesterolemia 60 plasma lipid 60 morphometric vertebral fractures 60 follicular lymphoma FL 60 INVEGA ® 60 neurosensory 60 elevated creatine phosphokinase 60 Coronary Artery Bypass Graft 60 HSCT 60 pharmacodynamic markers 60 subscale scores 60 conventional angiography 60 glomerular filtration 60 analgesic efficacy 60 Prospective Randomized 60 Psoriasis Area 60 KRAS status 60 aspartate aminotransferase AST 60 fasting insulin 60 CHAMPION PCI 60 Observational studies 60 OPT CHF 60 elevated ALT 60 homocysteine concentrations 60 urate levels 60 CTAP# Capsules 60 CIMZIA TM 60 contrast echocardiography 60 haematological 60 etiologic 60 Tiotropium 60 Symptom severity 60 mitochondrial toxicity 60 Alzheimer Disease Cooperative 60 Rating Scale MADRS 60 Ischemic 60 macrovascular complications 60 #F FDG PET 60 prospectively stratified 60 Secondary endpoints included 60 extrapyramidal symptoms 60 tolerability pharmacokinetics 60 CONCERTA ® 60 Levels Linked 60 ancrod 60 cardiometabolic risk 60 BYSTOLIC 60 preintervention 60 conditional logistic regression 60 immunohistochemical 60 renal toxicity 60 logistic regression analyzes 60 Low Density Lipoprotein Cholesterol 60 fasting plasma 60 hsCRP levels 60 proliferative diabetic retinopathy 60 serum lipid levels 60 serum PTH 60 HER2 expression 60 R# #mg BID 60 spirometric 60 Thrombolysis 60 Serious adverse reactions 60 See CLINICAL PHARMACOLOGY 60 dosage regimens 60 Acute Ischemic Stroke 60 aldosterone antagonists 60 Score IPSS 60 radiotherapy RT 60 laboratory abnormalities 60 Rheumatoid Arthritis Patients 60 CTEPH 60 SF #v# 60 differential gene expression 60 hemodynamic parameters 60 GAMMAGARD 60 Multiple logistic regression 60 BARI 2D 60 triglyceride concentrations 60 Multivariable logistic regression 60 thromboembolic complications 60 alicaforsen enema 60 concomitant medications 60 ADCS CGIC 60 DAS# scores 60 Xanafide 60 depressive symptomatology 60 dopaminergic therapy 60 Global Impression CGI 60 fasting plasma glucose 60 primary aldosteronism 60 Fulvestrant 60 Randomized Clinical Trial 60 Prognostic Value 60 ginkgo extract 60 PREZISTA r 60 Immunohistochemistry 60 Adverse Event 60 cilostazol 60 nicardipine 60 overactive bladder symptoms 60 colorectal liver metastases 60 antiangiogenic agents 60 topical NSAIDs 60 IBDQ 60 hawthorn extract 60 aldosterone antagonist 60 thyrotropin 60 hepatic fibrosis 60 urinary calcium 60 cytoreductive surgery 60 Celecoxib APC trial 60 pharmacological approaches 60 pentoxifylline 60 eplerenone 60 neuroimaging studies 60 GERD symptom 60 Bone Mineral Density 60 subclinical atherosclerosis 60 urinary calcium excretion 60 adjuvant therapies 59 Nonspecific 59 NMDA antagonists 59 antitumor efficacy 59 non selective NSAIDs 59 confounding variables 59 endothelin antagonists 59 Negative Symptoms 59 Coronary CTA 59 CT perfusion 59 myocardial reperfusion 59 CIMZIA TM certolizumab pegol 59 vasodilatation 59 left ventricular diastolic 59 reflux symptoms 59 GnRH agonists 59 Pioglitazone 59 Chronic Heart Failure 59 prognostic indicators 59 CANCIDAS 59 System IPSS 59 Aromatase Inhibitors 59 PCWP 59 carotid IMT 59 rFVIIa 59 haemodynamic 59 HIV HCV coinfected 59 Montgomery Åsberg Depression 59 FDG PET imaging 59 solifenacin 59 retrospective cohort 59 physiologic parameters 59 transthoracic 59 oxycodone CR 59 prognostic markers 59 DCE MRI 59 Acute Coronary Syndromes 59 Randomized Controlled Trials 59 NATRECOR R 59 duplex ultrasonography 59 bivariate analysis 59 APTIVUS 59 urinary N telopeptide 59 anti androgens 59 IGRAs 59 virologic response 59 Androxal TM 59 hyperalgesia 59 tolvaptan 59 semiquantitative 59 Hepatotoxicity 59 MGd 59 Reproducibility 59 cardiac dysfunction 59 INFERGEN 59 Cholesterol Levels SPARCL 59 clinicopathologic 59 blood Phe levels 59 AZILECT R 59 apolipoprotein B 59 AGILECT ® 59 APOE genotype 59 glycosylated hemoglobin levels 59 ACTEMRA TM 59 Hemoglobin A1c 59 postoperative atrial fibrillation 59 Radical prostatectomy 59 pharmacokinetic profiles 59 Patient Outcomes 59 perioperative morbidity 59 Clinical Relevance 59 metastatic neuroendocrine tumors 59 Venous Thromboembolism 59 composite endpoint 59 bronchial hyperresponsiveness 59 RE LY ® 59 adenotonsillectomy 59 Comorbidities 59 mucosal inflammation 59 skin sterol 59 elevated triglycerides 59 induced sputum 59 HCV RESPOND 2 59 cobiprostone 59 Hepatocellular Carcinoma HCC 59 International Prostate Symptom 59 Main Outcome Measures 59 therapeutic regimens 59 Cardiorespiratory fitness 59 completely resected 59 OAB symptoms 59 cardiovascular morbidity 59 Erythropoietic therapies may 59 RCTs 59 ARIXTRA 59 Demonstrated Significant 59 TEAEs 59 poststroke 59 nonhematologic adverse reactions 59 HMG CoA reductase inhibitors 59 overt nephropathy 59 proton MR spectroscopy 59 opioid analgesia 59 metabolic syndrome MetS 59 cerebral vasospasm 59 postoperative mortality 59 EBMT criteria 59 intermittent hypoxia 59 macrovascular disease 59 Stop Hypertension DASH diet 59 T1DM 59 Randomized Evaluation 59 HER2 overexpression 59 infliximab Remicade 59 neurocognitive impairment 59 clinically meaningful improvements 59 systolic hypertension 59 Hemodynamic 59 postoperative complication 59 zolmitriptan 59 antithrombotic therapy 59 brachial artery flow 59 NIH CPSI 59 CYT# potent vascular disrupting 59 Placebo Controlled Trial 59 thromboembolic 59 airway responsiveness 59 eNO 59 diabetic microvascular complications 59 Elevated triglycerides 59 recurrent venous thromboembolism 59 EDEMA3 trial 59 abnormal lipid 59 galiximab 59 ANCOVA 59 HAQ DI 59 comorbid conditions 59 clinicopathological features 59 urodynamic 59 Relapsing Remitting Multiple Sclerosis 59 chills fever headache 59 urinary oxalate 59 myeloproliferative diseases 59 adrenal function 59 Skin sterol 59 NATRECOR ® 59 efficacy endpoint 59 chromium picolinate supplementation 59 intima media thickness 59 paroxetine Paxil 59 MERIT ES 59 Bioavailability 59 Cognitive Impairment 59 Arterial Hypertension 59 carotid artery stenting CAS 59 Vasotrac 59 dosing cohort 59 Warfarin Coumadin 59 symptom severity 59 Non inferiority 59 thoracoscopic lobectomy 59 mRNA expression 59 LUTS 59 hematologic abnormalities 59 serum calcium 59 T2DM 59 LDB CPR 59 prostate carcinogenesis 59 transaminase elevations 59 intraoperative complications 59 platelet activation 59 Oral Fingolimod 59 ALT flares 59 Post hoc 58 lipid abnormalities 58 lipid lowering therapies 58 nasopharyngitis headache 58 APPRAISE 58 Aortic Stenosis 58 vasomotor 58 vesicoureteral reflux 58 Renal Cell Carcinoma RCC 58 postmarketing surveillance 58 transesophageal echocardiography 58 clinico pathological 58 mg BID dose 58 hemostatic efficacy 58 hemoglobin A1c levels 58 Cholinesterase Inhibitors 58 hyperphenylalaninemia HPA due 58 coronary calcification 58 lipid profiles 58 biostatistical analysis 58 impaired insulin secretion 58 angiotensin II receptor blockers 58 atherothrombotic disease 58 histologic 58 IMPROVE HF 58 insulin detemir 58 meta analytic 58 erection hardness 58 Prostate Cancer Recurrence 58 somatization disorder 58 angiographically 58 immunological responses 58 GFT# 58 intestinal motility 58 methacholine challenge 58 myocardial function 58 Ejection Fraction 58 CP CPPS 58 longitudinal observational study 58 p# biomarker 58 PSA kinetics 58 clinical endpoints 58 Neuropsychiatric Inventory 58 GERD migraine headaches 58 extracellular dopamine 58 denervation 58 NYHA 58 Angiotensin converting enzyme 58 oral anticoagulant therapy 58 NNT = 58 endometrial carcinoma 58 subscales 58 unfavorable cytogenetics 58 hematologic toxicity 58 baseline HbA1c 58 cTnT levels 58 bazedoxifene conjugated estrogens 58 coronary revascularizations 58 urine albumin 58 serum vitamin D 58 cardiac biomarkers 58 Pharmacologic 58 BMI z 58 Myocardial Perfusion 58 secondary endpoint 58 HbA 1C 58 Celecoxib 58 dysglycemia 58 adenoma recurrence 58 pathophysiological mechanisms 58 QTc intervals 58 Severity Index PASI 58 Randomized trials 58 revascularization procedures 58 ADAS cog 58 GLIADEL R Wafer 58 Metastatic Renal Cell Carcinoma 58 efficacy tolerability 58 flow mediated dilation 58 abdominal adiposity 58 ImmuKnow 58 bezafibrate 58 symptomatic hyponatremia 58 EEG abnormalities 58 posttreatment 58 RQ PCR 58 risperidone Risperdal 58 pulmonary artery banding 58 CAMMS# 58 CaPre TM 58 platelet reactivity 58 efficacy endpoints 58 Intervention Trial 58 NLX P# 58 hepatic lesions 58 icatibant 58 IMPACT DCM 58 euthymic patients 58 Health Assessment Questionnaire 58 hypoperfusion 58 analgesic medications 58 epoetin alpha 58 HDRS 58 EXJADE 58 AA Amyloidosis 58 Antitumor 58 Exacerbations 58 Coronary Artery Calcium 58 Controlled Trial 58 Lipid Lowering Treatment 58 RECIST Response Evaluation Criteria 58 post thrombotic syndrome 58 Multivariate analysis 58 Teriflunomide 58 SYNTAX trial 58 CIN2 + 58 clinically meaningful improvement 58 Inflammatory Markers 58 Capacity FVC 58 HAART regimens 58 interobserver 58 multivariate regression analysis 58 ACE Inhibitors 58 recurrent glioblastoma multiforme 58 urate lowering 58 carotid stenosis 58 lipid lowering therapy 58 anti JCV antibodies 58 chronic periodontitis 58 mammographic density 58 postoperative pulmonary 58 myocardial uptake 58 parasitological 58 anticholinergic medications 58 psychosocial variables 58 radiochemotherapy 58 specific antigen PSA 58 cytoreductive nephrectomy 58 Hematological 58 cystoscopic 58 neutropaenia 58 cMET 58 preclinical pharmacokinetic 58 intensive statin therapy 58 AVERROES 58 liver metastasis 58 transient elastography 58 Platelet Inhibition 58 serum urate 58 cerebral ischemia 58 Recurrent Breast Cancer 58 clinicopathological 58 oral anticoagulation 58 transcranial Doppler ultrasound 58 Baseline characteristics 58 dietary carbohydrate 58 Dialysis Outcomes 58 Chemotherapeutic Agents 58 kidney urologic 58 Antihypertensive 58 Randomized Trials 58 anticholinergic agents 58 pharmacologic treatments 58 canakinumab 58 hyperhomocysteinemia 58 preterm newborns 58 serum biomarkers 58 visilizumab 58 ARCOXIA 58 aminotransferase 58 serotonin synthesis 58 thromboembolic disease 58 N telopeptide 58 plasma lipids 58 periprocedural 58 alanine aminotransferase ALT 58 glycemia 58 hypersensitivity allergic reactions 58 BEXXAR therapeutic regimen 58 incontinence episodes 58 Diabetic Macular Edema 58 chest radiographs 58 epithelial tumors 58 EGFR HER2 58 Relapsing Multiple Sclerosis 58 cTnT 58 psychiatric morbidity 58 Demonstrate Significant 58 sonographic diagnosis 58 GRNCM1 58 REG1 58 psychiatric comorbidities 58 dirucotide MBP# 58 antiviral efficacy 58 STAT3 signaling 58 androgen suppression 58 INTERHEART study 58 Histopathologic 58 multivariable analyzes 58 EMPOWER ™ 58 Postoperative 58 Cognitive Function 58 bone scintigraphy 58 preclinical efficacy 58 neuropathies 58 hyperglycaemia 58 clomipramine 58 Lubiprostone 58 APTIVUS ritonavir 58 Pharmacokinetic 58 RE LY trial 58 fasting plasma glucose FPG 58 prostate cancer PCa 58 HRQoL 58 Generalized Anxiety Disorder 58 immunohistochemical analysis 58 Logistic regression 58 cognitive behavioral therapies 58 electroencephalographic 58 urine cytology 58 hypoglycemic episodes 58 thrombotic complications 58 MEND CABG 58 prospective observational cohort 58 beta carotene supplementation 58 unmeasured confounders 58 neuropathological 58 eTag assays 58 Immunogenicity 58 radiographic outcomes 58 sweat chloride 58 postprocedure 58 TLR antagonists 58 achieved statistical significance 58 neurocognitive functioning 58 pharmacokinetics PK 58 androgen excess 58 LHRH antagonists 58 ritonavir boosted protease inhibitor 58 irbesartan 58 HCV SPRINT 58 ONTARGET 58 serologically active patients 58 GH deficiency 58 lipid elevations 58 Left Ventricular Hypertrophy 58 Unified Parkinson Disease 58 univariate 58 mu opioid 58 Diovan HCT 58 Nonalcoholic Fatty Liver Disease 58 JAK Inhibitor 58 clinical pharmacology studies 58 Demonstrates Efficacy 58 histopathological 58 histologic subtypes 58 hypoglycemic events 58 symptom checklist 58 Endothelial function 58 prucalopride 58 retinal thickness 58 antidiabetic medications 58 prostate cancer CaP 58 Carotid Stenting 58 dietary interventions 58 flutamide 58 hippocampal atrophy 58 serum phosphate 58 definite stent thrombosis 58 Gastrointestinal Stromal Tumors 58 gallium nitrate 58 serum lipids 58 Aggressive Reduction 58 CT Angiography 58 esophageal reflux 58 neuropsychiatric symptoms 57 intracranial hemorrhage ICH 57 thorough QT 57 Breast Density 57 surrogate endpoint 57 basal bolus regimen 57 antidiabetic drugs 57 Atopic Dermatitis 57 bivariate analyzes 57 plasma homocysteine 57 HPA axis 57 infarct size 57 gastric carcinoma 57 pharmacodynamic effects 57 pharmacodynamic 57 covariates 57 cediranib 57 residual confounding 57 QIDS SR 57 divalproex sodium 57 daytime alertness 57 ARB telmisartan 57 pain palliation 57 ximelagatran 57 intestinal permeability 57 hepatic arterial 57 mu opioid agonist analgesics 57 antihypertensive agents 57 WARNINGS Myopathy Rhabdomyolysis 57 Diabetic Foot Ulcer 57 vascular reactivity 57 patients undergoing CABG 57 NYHA functional class 57 D Dimer 57 Menstrual Pain 57 NPM1 mutation 57 TDF FTC 57 corticosteroid dose 57 CNS LS 57 Follicular Lymphoma 57 Stent Thrombosis 57 vitreous floaters 57 preoperative chemotherapy 57 Secondary Hyperparathyroidism 57 SGOT 57 Cytotoxicity 57 prospective longitudinal 57 artery stenosis 57 angiotensin converting enzyme inhibitors 57 Nutritional Status 57 fluoxetine paroxetine 57 neurocognitive deficits 57 intravitreal injections 57 Physical Function 57 Patient Populations 57 hypercalciuria 57 torsemide ER 57 XIENCE V PROMUS Stent 57 PRoFESS 57 intravesical therapy 57 S. aureus isolates 57 somatoform disorders 57 mycophenolate mofetil 57 ß blockers 57 Complications Trial 57 serum BDNF 57 Restenosis 57 fasting glucose levels 57 neurophysiologic 57 covariance ANCOVA 57 crizotinib PF # 57 ALSFRS R 57 indiplon capsules 57 fluoxetine Prozac 57 Randomized Double blind 57 stratifying patients 57 cognitive affective 57 subthreshold depression 57 Risk Stratification 57 MADIT CRT trial 57 Cytogenetic 57 CDAI 57 emotional lability 57 Data Extraction 57 Vascugel ® 57 AVOREN 57 mesalamine granules 57 carotid artery narrowing 57 prodromal symptoms 57 Left Ventricular Dysfunction 57 atypical antipsychotic medications 57 non squamous NSCLC 57 pharmacologic stress 57 nonfatal MI 57 arterial calcification 57 hematopoietic cancers 57 perioperative mortality 57 neurotrophic 57 Erectile function 57 PLMs 57 Antisoma AS# 57 serum calcium levels 57 albumin excretion rate 57 Patients Receiving 57 cardiac perfusion 57 antiplatelet drugs 57 prognostic factors 57 elevated creatinine 57 plasma creatinine 57 macroalbuminuria 57 potassium sparing diuretics 57 Coronary artery bypass grafting 57 PSN# [002] 57 allergic airway inflammation 57 adiponectin levels 57 Placebo Controlled Study 57 aspirin NSAIDs 57 carotid angioplasty 57 multivariable analysis 57 serum uric acid 57 hypoglycaemic episodes 57 STRATEGY FOR AN OPEN 57 HOMA IR 57 Traficet EN 57 myocardial ischaemia 57 pancreatectomy 57 surrogate markers 57 salivary cortisol 57 Univariate 57 antidepressant efficacy 57 OADs 57 Creatinine 57 longitudinal cohort study 57 Microalbuminuria 57 nerve conduction velocity 57 carotid bruit 57 nonrandomized 57 NHANES III 57 albuminuria 57 antibiotic prophylaxis 57 PROSTASCINT R 57 Antiviral Activity 57 urolithiasis 57 idiopathic Parkinson disease 57 antitumor effect 57 Solid Tumors 57 reactogenicity 57 plasma renin activity 57 physiologic responses 57 perfusion MRI 57 Unfractionated Heparin 57 lesional 57 lymphopenia 57 Tasigna prolongs 57 statin monotherapy 57 CYP#D# inhibitor 57 MoxDuo IR 57 GEM OS2 57 echocardiographic 57 antiplatelet medications 57 LDL cholesterol lowering 57 bioavailable testosterone 57 alexithymia 57 ER CHOP 57 HIF PHI 57 sonographic findings 57 poststroke depression 57 nausea photophobia 57 lamotrigine 57 Lipid Levels 57 Carotid Revascularization Endarterectomy vs. 57 vascular endothelial dysfunction 57 Polyp Prevention Trial 57 Phase IIB 57 glycated hemoglobin HbA1c 57 patients evaluable 57 pressor response 57 percutaneous vertebroplasty 57 multivariate regression 57 pharmacokinetics pharmacodynamics 57 Platelet counts 57 WOMAC pain 57 undetectable HBV DNA 57 chronic prostatitis chronic 57 REYATAZ ritonavir 57 QoL 57 serum lipid 57 neurologic complications 57 ALT AST 57 PreCISe study 57 Coronary Angiography 57 chemoprevention trials 57 hemoglobin A1c HbA1c 57 liver transplant recipients 57 salivary flow 57 actigraphy 57 Pharmacokinetics PK 57 ThermoDox ® clinical 57 dose proportionality 57 ACCORD Lipid 57 timepoints 57 neuropsychiatric diseases 57 prognostic significance 57 WOMAC scores 57 aspirin clopidogrel 57 Anthracycline 57 neuroleptic 57 neuropsychological assessment 57 eprotirome 57 salmeterol fluticasone 57 Hypotension 57 DAVANAT R exhibits 57 Treatment Outcome 57 nabilone 57 Main Outcome Measure 57 candesartan cilexetil 57 oral rivaroxaban 57 Orthostatic Hypotension 57 solithromycin 57 Double Blind Randomized 57 antiangiogenic therapy 57 liver resection 57 bacterial prostatitis 57 cystatin C 57 neuropathologic